Traders should monitor future sales trends of JORNAY PM in upcoming earnings reports to assess whether the campaign translates into measurable revenue growth. No immediate financial impact is expected.
Price Chart
Executive Summary
Collegium Pharmaceutical announced a partnership with Paris Hilton on a public awareness campaign called 'Embrace Your Sparkle' to reduce stigma and encourage dialogue around adult ADHD. The campaign highlights Hilton's personal experience managing ADHD with JORNAY PM, Collegium's evening-dosed methylphenidate product indicated for ADHD in patients 6 years and older.
Key Facts
- Collegium Pharmaceutical partnered with Paris Hilton on an ADHD awareness campaign called 'Embrace Your Sparkle'.
- The campaign promotes open dialogue about ADHD, particularly in adults, and emphasizes individualized treatment plans.
- Paris Hilton shares her personal ADHD journey and use of JORNAY PM (methylphenidate HCl) as part of her treatment regimen.
- JORNAY PM is an extended-release CNS stimulant taken in the evening to provide symptom control from morning through early evening.
- No financial terms, revenue impact, or sales data were disclosed in the press release.
Financial Impact
No quantifiable financial impact disclosed; potential indirect benefit to JORNAY PM brand awareness.
Risk Factors
- Public campaigns involving celebrities carry reputational risk if perceived as exploitative or if safety concerns arise with the promoted product.
- JORNAY PM is a Schedule II controlled substance with risks of abuse, dependence, and serious cardiovascular or psychiatric side effects, which may limit prescribing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3248249 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | Court Ruling | $28.74 $22.38 | ▼ −22.13% | ▼ −20.18% | $22.07 (−23.21%) |
Aug 13, 2026 7w ago | 8-K | $28.15 $22.75 | ▼ −19.18% | ▼ −17.44% | $22.07 (−21.60%) |
Aug 6, 2026 8w ago | 8-K | $29.11 $23.70 | ▼ −18.58% | ▼ −19.18% | $22.07 (−24.18%) |
May 15, 2026 19w ago | Insider Cluster | $33.65 $34.65 | ▲ +2.97% | ▲ +1.39% | $22.07 (−34.41%) |
May 12, 2026 20w ago | Press Release | $35.69 $34.80 | ▼ −2.49% | ▼ −0.77% | $22.07 (−38.16%) |
May 11, 2026 20w ago | 144 | $35.81 $34.40 | ▼ −3.94% | ▼ −3.63% | $22.07 (−38.37%) |
Apr 23, 2026 23w ago | Press Release | $32.28 $34.22 | ▲ +6.01% | ▲ +1.38% | $22.07 (−31.63%) |
Apr 7, 2026 25w ago | 8-K | $33.43 $35.32 | ▲ +5.65% | ▼ −2.89% | $22.07 (−33.98%) |
Mar 19, 2026 28w ago | Press Release | $36.30 $34.41 | ▼ −5.21% | ▼ −12.83% | $22.07 (−39.20%) |
Mar 3, 2026 30w ago | Press Release | $39.99 $33.07 | ▼ −17.30% | ▼ −12.90% | $22.07 (−44.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access